L09 #ACR22 MTX in Post-Roe Era 6% patients reported barrier to MTX access 1 pt noted restriction to HCQ Most delays due to pharmacy - told due to pregnancy/abortion concerns or unexplained reason Rare BUT Real Problem - shows importance of @ACRheumDC advocacy efforts @RheumNow https://t.co/8Yr7nynzN6

L10 #ACR22 Efgartigimod in IMNM IgG1 Fc fragment targeting neonatal Fc receptor (FcRn) Restored grip and muscle strength in mice studies with pathogenic anti-HMGCR+ (p<0.05) Total IgG and anti-HMGCR Ab became undetectable @RheumNow

Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-analysis of CARES trial. @RheumNow #ACR22 Abstr#1809 https://t.co/I6evAl4BLd https://t.co/n70FvYah1p

• Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients:…

Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW

• Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic a…

Gurwith et al ABP-671 a URAT1 inhibitor effectively lowers serum urate @RheumNow #ACR22 Abstr#1822 https://t.co/hXAQoVHrLH https://t.co/saVqu4kbnr

• A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a…

L14 #ACR22 Bimekizumab BE MOBILE 1 and 2 Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure. AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%) @RheumNow https://t.co/G31PrfqtVu

L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS P3b: SEC 150 mg v SEC 300 v SDZ-ADL Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance Hard to assess as overall, low rate of progression @RheumNow

Lindegren et al. Dairy intake and RA risk in Sweden. Nested case-control. High regular milk intake assoc increased risk (OR 1.90) High cheese assoc decresaed risk (OR 0.52) @RheumNow #ACR22 Abstr#1758 https://t.co/jUz3SJBf4Y https://t.co/ZykW3NjSrK

• Intake of Dairy Products as a Risk Factor for Rheumatoid Arthritis; A Nested Ca…

A spicy result. say NO to turmeric in #rheumatoidarthritis Eat it on food, but don’t expect it to help your joints. @RheumNow #ACR22 https://t.co/1mZBm3rYAA

• https://twitter.com/drdavidliew/status/1592148453504737280

Utamawatin et al. DB-RCT of Triamcinolone 10mg vs 40mg for knee OA. No difference! Wonder if 10mg would be better than saline? @RheumNow #ACR22 Abstr#1890 https://t.co/vcKze7mSf4 https://t.co/ErEkmUN0Wp

• The Efficacy of Intra-articular Triamcinolone Acetonide 10 mg vs. 40 mg in Pati…

Problem w antibodies to prevent #COVID19 infection in rheumatic Pts is that they are not as good in variants that are more prominent ex Omicron strains. But should we use in high risk Pts ex long rituximab users? I do in this group. @RheumNow #ACR22 https://t.co/A8soYbg9ZD

• https://twitter.com/ericdeinmd/status/1592153383497977857

Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher administration site reactions in SC. @RheumNow #ACR22 Abstr#1769 https://t.co/KnYlvifDlr https://t.co/VnKOYs86Xz

• Comparative Evaluation of Adverse Events Associated with Subcutaneous Inflixima…

Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow 🚬519 ever smokers 🚭767 never smokers 💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO ✋Overall, efficacy was generally comparable in ever v. never 🚬

Lillegraven @SiriLillegraven ARCTIC REWIND. RA patients flare-free on half-dose csDMARD x 12 months - randomised to continue or stop. Flare 38% vs 17% over 12 months. DAS remission 96% vs 90%. Absence radiograph prog 84% vs 69% @RheumNow #ACR22 Abstr#2013 https://t.co/uOwd8Io5wZ https://t.co/SKWPE7GBrx

• Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlle…